↓ Skip to main content

Endocannabinoids

Overview of attention for book
Attention for Chapter 8: Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#48 of 496)
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
1 news outlet
twitter
10 tweeters
facebook
1 Facebook page
googleplus
1 Google+ user
reddit
1 Redditor

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
216 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Chapter number 8
Book title
Endocannabinoids
Published in
Handbook of experimental pharmacology, January 2015
DOI 10.1007/978-3-319-20825-1_8
Pubmed ID
Book ISBNs
978-3-31-920824-4, 978-3-31-920825-1
Authors

Fernández-Ruiz, Javier, Romero, Julián, Ramos, José A, Javier Fernández-Ruiz, Julián Romero, José A. Ramos

Editors

Roger G. Pertwee

Abstract

This review focuses on the role of the endocannabinoid signaling system in controlling neuronal survival, an extremely important issue to be considered when developing new therapies for neurodegenerative disorders. First, we will describe the cellular and molecular mechanisms, and the signaling pathways, underlying these neuroprotective properties, including the control of glutamate homeostasis, calcium influx, the toxicity of reactive oxygen species, glial activation and other inflammatory events; and the induction of autophagy. We will then concentrate on the preclinical studies and the few clinical trials that have been carried out targeting endocannabinoid signaling in three important chronic progressive neurodegenerative disorders (Parkinson's disease, Huntington's chorea, and Alzheimer's disease), as well as in other less well-studied disorders. We will end by offering some ideas and proposals for future research that should be carried out to optimize endocannabinoid-based treatments for these disorders. Such studies will strengthen the possibility that these therapies will be investigated in the clinical scenario and licensed for their use in specific disorders.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 216 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 2 <1%
Austria 1 <1%
Brazil 1 <1%
Spain 1 <1%
United States 1 <1%
Unknown 210 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 43 20%
Student > Ph. D. Student 39 18%
Student > Master 34 16%
Researcher 24 11%
Student > Doctoral Student 14 6%
Other 35 16%
Unknown 27 13%
Readers by discipline Count As %
Medicine and Dentistry 36 17%
Neuroscience 29 13%
Biochemistry, Genetics and Molecular Biology 28 13%
Agricultural and Biological Sciences 28 13%
Pharmacology, Toxicology and Pharmaceutical Science 19 9%
Other 42 19%
Unknown 34 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2017.
All research outputs
#1,350,091
of 16,261,897 outputs
Outputs from Handbook of experimental pharmacology
#48
of 496 outputs
Outputs of similar age
#26,550
of 251,749 outputs
Outputs of similar age from Handbook of experimental pharmacology
#1
of 7 outputs
Altmetric has tracked 16,261,897 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 496 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 251,749 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them